Skip to content

Trip HF Study: Triple Resynchronization in Paced Heeart Failure Patients

Triple Resynchronization in Paced Heart Failure Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00187265
Enrollment
Unknown
Registered
2005-09-16
Start date
2003-04-30
Completion date
2005-10-31
Last updated
2019-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart Failure, Ventricular Dyssynchrony

Brief summary

The purpose of this study is to evaluate the feasibility of permanent biventricular pacing using three ventricular leads, and its efficacy in terms of inter and intra-ventricular resynchronization, in patients with congestive heart failure and a non-functional atrium (chronic AF).

Interventions

DEVICECardiac Resynchronization Therapy

Sponsors

Abbott Medical Devices
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
SINGLE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

• NYHA class III-IV congestive heart failure, in spite of optimal medical treatment for their congestive heart failure for 1 month. The medical treatment must include a 40 mg/day minimum dose of furosemide (or equivalent); * Permanent atrial fibrillation (AF); * Left ventricular ejection fraction (LVEF) ≤ 35%; * Indication for a pacemaker implantation for a permanent and symptomatic bradycardia, or already implanted pacemaker under the condition that leads positioning corresponds to the criteria described in the protocol; * Aortic pre-ejection delay at least equal to 140 ms.

Exclusion criteria

* Indication for a cardiac defibrillator; * Having presented a myocardial infarct within the previous 3 months; * Having undergone cardiac surgery or coronary revascularization procedure within the previous 3 months, or being scheduled for such procedures; * Presenting chronic pulmonary insufficiency; * Patients whose congestive heart failure requires the use of an intravenous inotropic support; * Presenting a dysthyreosis; * Having a life expectancy of less than one year, for other reasons than the congestive heart failure; * Unable to be followed-up in the scope of the study for geographical reasons; * Having refused to give their consent; * Minors (age \< 18 years) and pregnant women.

Design outcomes

Primary

MeasureTime frame
Z-ratio

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026